GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Deferred Tax

Aravive (STU:VE11) Deferred Tax

: €0.00 Mil (TTM As of Sep. 2023)
View and export this data going back to 2017. Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Aravive's change in deferred tax for the three months ended in Sep. 2023 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Aravive Deferred Tax Historical Data

The historical data trend for Aravive's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => - [6] => - [7] => - [8] => - [9] => - )
Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Deferred Tax
 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Deferred Tax Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aravive Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aravive Deferred Tax Related Terms

Thank you for viewing the detailed overview of Aravive's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (STU:VE11) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Deferred Tax
Comparable Companies
BNTC VYNE ONVO ENZN CMRA INTI GRTX VIRI BRTX TMBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ARAV:USA VE11:Germany
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Website
https://www.aravive.com
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines